Department of Neurosurgery and Spine Surgery, University Hospital Essen, Germany (A.E., L.S., L.R., M.G., A.N.S., T.F.D., M.D.O., O.G., Y.A., P.D., U.S., R.J.).
Center for Translational Neuroscience and Behavioral Science (C-TNBS), University of Duisburg-Essen, Germany (A.E., L.S., L.R., M.G., A.N.S., T.F.D., M.D.O., O.G., Y.A., P.D., U.S., R.J.).
Stroke. 2024 Sep;55(9):2305-2314. doi: 10.1161/STROKEAHA.124.047594. Epub 2024 Aug 5.
Carotid siphon calcification (CSC) serves as a marker of atherosclerosis and therefore may influence the outcome after subarachnoid hemorrhage (aSAH). We aimed to analyze the impact of CSC on neurological outcomes, ischemia, and vasospasm.
A total of 716 patients with aSAH were treated between December 2004 and June 2016 in our central European tertiary neurovascular care center in Essen, Germany. CSC was recorded using the Woodcock scale (grades 0-3) on a computed tomography scan. Study end points included an unfavorable outcome at 6 months post-aSAH (modified Rankin Scale score ≥4), vasospasm, and early cerebral ischemia (72 hours) and delayed cerebral ischemia (delayed cerebral ischemia; >72 hours) in the follow-up computed tomography scans. The associations were adjusted for patients' baseline characteristics and secondary complications. Finally, within a subgroup analysis, patients with and without daily aspirin intake after endovascular aneurysm occlusion were compared.
Increasing grades of CSC were associated with lower rates of vasospasm in the anterior circulation. Severe CSC (grade 3) was independently related to the risk of an unfavorable outcome (adjusted odds ratio [aOR], 4.06 [95% CI, 1.98-8.33]; <0.001) and early cerebral ischemia (aOR, 1.58 [95% CI, 1.03-2.43]; =0.035) but not delayed cerebral ischemia (aOR, 1.08 [95% CI, 0.67-1.73]; =0.763). In the aspirin subgroup analysis, the negative effect of severe CSC on functional outcome remained significant only in aSAH cases without aspirin (aOR, 5.47 [95% CI, 2.38-12.54]; <0.001). In contrast, there was no association between severe CSC and unfavorable outcomes among individuals with daily aspirin intake (aOR, 0.84 [95% CI, 0.59-4.21]; =0.603).
Our data suggest CSC as a cerebrovascular risk factor resulting in higher rates of early cerebral ischemia and unfavorable outcomes after aSAH. However, by increasing arterial stiffness, CSC might lower the probability of vasospasm, which could explain the missing link between CSC and delayed cerebral ischemia. Additionally, aspirin intake seems to potentially mitigate the negative impact of CSC on aSAH outcome. Further investigations are needed to confirm the observations from the present study.
颈内虹吸段钙化(CSC)是动脉粥样硬化的标志物,因此可能影响蛛网膜下腔出血(aSAH)的预后。我们旨在分析 CSC 对神经功能结局、缺血和血管痉挛的影响。
2004 年 12 月至 2016 年 6 月,我们在德国埃森的中欧三级神经血管护理中心治疗了 716 例 aSAH 患者。CSC 使用 Woodcock 量表(0-3 级)在计算机断层扫描(CT)上记录。研究终点包括 aSAH 后 6 个月的不良结局(改良 Rankin 量表评分≥4)、血管痉挛、早期脑缺血(72 小时)和随访 CT 扫描中的迟发性脑缺血(>72 小时)。调整了患者的基线特征和次要并发症的影响。最后,在亚组分析中,比较了血管内动脉瘤闭塞后有和无每日阿司匹林治疗的患者。
CSC 程度增加与前循环中血管痉挛发生率降低相关。严重 CSC(等级 3)与不良结局的风险独立相关(调整后的优势比[aOR],4.06[95%置信区间,1.98-8.33];<0.001)和早期脑缺血(aOR,1.58[95%置信区间,1.03-2.43];=0.035),但与迟发性脑缺血无关(aOR,1.08[95%置信区间,0.67-1.73];=0.763)。在阿司匹林亚组分析中,严重 CSC 对功能结局的负面影响仅在无阿司匹林的 aSAH 患者中仍有意义(aOR,5.47[95%置信区间,2.38-12.54];<0.001)。相比之下,每日服用阿司匹林的患者中,严重 CSC 与不良结局之间没有关联(aOR,0.84[95%置信区间,0.59-4.21];=0.603)。
我们的数据表明 CSC 是脑血管危险因素,导致 aSAH 后早期脑缺血和不良结局的发生率增加。然而,CSC 通过增加动脉僵硬度,降低血管痉挛的可能性,这可以解释 CSC 与迟发性脑缺血之间缺失的联系。此外,阿司匹林的摄入似乎可能减轻 CSC 对 aSAH 预后的负面影响。需要进一步的研究来证实本研究的观察结果。